SEC ownership of NOVAVAX INC

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001000694.

Comparable stake leader

SHAH CAPITAL MANAGEMENT

Disclosed value leader

SHAH CAPITAL MANAGEMENT

Comparable rows

50/50

Latest evidence

30 Jun 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
SHAH CAPITAL MANAGEMENT
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
30 Jun 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001000694
Issuer location
Gaithersburg, MD

Ownership snapshot

Top shareholders of NOVAVAX INC (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
SHAH CAPITAL MANAGEMENT
Disclosed value leader
SHAH CAPITAL MANAGEMENT
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F 13D/G Lead comparable stake: 9% 13D/G row: SHAH CAPITAL MANAGEMENT Showing 1-8 of 50 holder rows.

Quick read

SHAH CAPITAL MANAGEMENT leads the comparable SEC ownership view at 9%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens SHAH CAPITAL MANAGEMENT's linked filing trail.
Comparable ownership Top 5
SHAH CAPITAL MANAGEMENT 9%
BlackRock, Inc. 8.4%
STATE STREET CORP 7.1%
VANGUARD CAPITAL MANAGEMENT LLC 5.1%
BANK OF AMERICA CORP /DE/ 4.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
SHAH CAPITAL MANAGEMENT
13F 13D/G
Company · Himanshu H. Shah
9%
from 13D/G
$133,439,735
14,165,577 shares
30 Jun 2026
BlackRock, Inc.
13F 13D/G
Company
8.4%
from 13D/G
$131,379,618
13,946,881 shares
30 Jun 2026
STATE STREET CORP
13F 13D/G
Company · STATE STREET CORPORATION
7.1%
from 13D/G
$110,595,981
11,740,550 shares
30 Jun 2026
VANGUARD CAPITAL MANAGEMENT LLC
13F 13D/G
Company · Vanguard Capital Management
5.1%
from 13D/G
$68,365,170
7,257,449 shares
30 Jun 2026
BANK OF AMERICA CORP /DE/
13D/G 13F
Company
4.1%
$54,174,940
6,655,398 shares
-$13,513,474 31 Mar 2026
VANGUARD PORTFOLIO MANAGEMENT LLC
13F
Company
13F
4.6%
$71,667,322
7,607,996 shares
30 Jun 2026
Sanofi
13F
Company
13F
4.2%
$64,814,131
6,880,481 shares
30 Jun 2026
D. E. Shaw & Co., Inc.
13F
Company
13F
3.4%
$53,231,525
5,650,905 shares
30 Jun 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 20 Sep 2025.

Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-20 of 22 reporting-owner rows connected to NOVAVAX INC. Open a relationship link for the CIK-to-CIK filing trail.

Rows
22
Largest Forms 3/4/5 holder
John C. Jacobs
Net 12M change
$0
Latest report
18 Jun 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
John C. Jacobs President and CEO, Director $8,425,812 Mixed 03 Mar 2026
Elaine O'Hara EVP, Chief Strategy Officer $3,585,213 Mixed 03 Mar 2026
James Patrick Kelly EVP, CFO and Treasurer $3,036,751 Mixed 07 Mar 2026
Mark J. Casey EVP, Chief Legal Officer $2,256,220 Mixed 03 Mar 2026
Filip Dubovsky President, R&D $1,226,227 Mixed 17 Jun 2024
David M. Mott Director $976,017 Mixed 18 Jun 2026
DOUGLAS RICHARD Director $922,700 Mixed 18 Jun 2026
John Trizzino President and COO $808,572 Mixed 07 Mar 2025
James F. Young Director $806,810 Mixed 24 Dec 2024
Ruxandra Draghia-Akli EVP, Research & Development $805,863 Mixed 02 Mar 2026
Gregg H. Alton Director $714,845 Mixed 18 Jun 2026
Margaret G. Mcglynn Director $688,659 Mixed 18 Jun 2026
Rachel K. King Director $685,419 Mixed 18 Jun 2026
Richard J. Rodgers Director $597,843 Mixed 18 Jun 2026
John W. Shiver Director $592,398 Mixed 18 Jun 2026
Robert Edward Walker Evp, R&D $279,902 Mixed 14 Apr 2026
Stanley C. Erck President and CEO, Director $195,098 Mixed 14 Dec 2022
Gregory M. Glenn President, R&D $149,795 Mixed 06 Mar 2023
Gary C. Evans Director $83,279 Mixed 17 Jun 2021
Charles W. Newton Director $77,492 Mixed 18 Jun 2026

Recent insider transactions for NOVAVAX INC

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Richard J. Rodgers NVAX Common Stock Options Exercise 66.3% 18,880 47,370 20 Jun 2026 Direct
Richard J. Rodgers NVAX Restricted Stock Units Options Exercise -100% -18,880 0 20 Jun 2026 Direct
Rachel K. King NVAX Common Stock Options Exercise 75% 18,880 44,070 20 Jun 2026 Direct
Rachel K. King NVAX Restricted Stock Units Options Exercise -100% -18,880 0 20 Jun 2026 Direct
Douglas Richard NVAX Common Stock Options Exercise 34.7% 18,880 73,220 20 Jun 2026 Direct
Douglas Richard NVAX Restricted Stock Units Options Exercise -100% -18,880 0 20 Jun 2026 Direct
Margaret G. Mcglynn NVAX Common Stock Options Exercise 73.8% 18,880 44,468 20 Jun 2026 Direct
Margaret G. Mcglynn NVAX Restricted Stock Units Options Exercise -100% -18,880 0 20 Jun 2026 Direct
David M. Mott NVAX Common Stock Options Exercise 31% 18,880 79,770 20 Jun 2026 Direct
David M. Mott NVAX Restricted Stock Units Options Exercise -100% -18,880 0 20 Jun 2026 Direct
Gregg H. Alton NVAX Common Stock Options Exercise 65.5% 18,880 47,685 20 Jun 2026 Direct
Gregg H. Alton NVAX Restricted Stock Units Options Exercise -100% -18,880 0 20 Jun 2026 Direct
Richard J. Rodgers NVAX Restricted Stock Units Award 14,180 14,180 18 Jun 2026 Direct
Richard J. Rodgers NVAX Stock Option (Right to Buy) Award 21,270 21,270 18 Jun 2026 Direct
Rachel K. King NVAX Restricted Stock Units Award 14,180 14,180 18 Jun 2026 Direct
Rachel K. King NVAX Stock Option (Right to Buy) Award 21,270 21,270 18 Jun 2026 Direct
Douglas Richard NVAX Restricted Stock Units Award 14,180 14,180 18 Jun 2026 Direct
Douglas Richard NVAX Stock Option (Right to Buy) Award 21,270 21,270 18 Jun 2026 Direct
Margaret G. Mcglynn NVAX Restricted Stock Units Award 14,180 14,180 18 Jun 2026 Direct
Margaret G. Mcglynn NVAX Stock Option (Right to Buy) Award 21,270 21,270 18 Jun 2026 Direct
David M. Mott NVAX Restricted Stock Units Award 14,180 14,180 18 Jun 2026 Direct
David M. Mott NVAX Stock Option (Right to Buy) Award 21,270 21,270 18 Jun 2026 Direct
Gregg H. Alton NVAX Restricted Stock Units Award 14,180 14,180 18 Jun 2026 Direct
Gregg H. Alton NVAX Stock Option (Right to Buy) Award 21,270 21,270 18 Jun 2026 Direct
John W. Shiver NVAX Restricted Stock Units Award 14,180 14,180 18 Jun 2026 Direct
John W. Shiver NVAX Stock Option (Right to Buy) Award 21,270 21,270 18 Jun 2026 Direct
Charles W. Newton NVAX Restricted Stock Units Award 14,180 14,180 18 Jun 2026 Direct
Charles W. Newton NVAX Stock Option (Right to Buy) Award 21,270 21,270 18 Jun 2026 Direct
Charles W. Newton NVAX Common Stock Options Exercise 9,520 9,520 25 Apr 2026 Direct
Charles W. Newton NVAX Restricted Stock Units Options Exercise -33.3% -9,520 19,040 25 Apr 2026 Direct
Robert Edward Walker NVAX Restricted Stock Units Award 66,000 6,600 14 Apr 2026 Direct
Robert Edward Walker NVAX Stock Option (Right to Buy) Award 99,500 99,500 14 Apr 2026 Direct
John W. Shiver NVAX Common Stock Options Exercise 7,947 7,947 10 Mar 2026 Direct
John W. Shiver NVAX Restricted Stock Units Options Exercise -33.3% -7,947 15,893 10 Mar 2026 Direct
James Patrick Kelly NVAX Common Stock Tax liability -4.33% -5,904 130,599 07 Mar 2026 Direct
James Patrick Kelly NVAX Common Stock Options Exercise 9.84% 12,223 136,503 07 Mar 2026 Direct
James Patrick Kelly NVAX Restricted Stock Units Options Exercise -100% -12,223 0 07 Mar 2026 Direct
James Patrick Kelly NVAX Common Stock Tax liability -14.4% -20,850 124,280 03 Mar 2026 Direct
James Patrick Kelly NVAX Common Stock Options Exercise 42.3% 43,167 145,130 03 Mar 2026 Direct
James Patrick Kelly NVAX Restricted Stock Units Options Exercise -33.3% -43,167 86,333 03 Mar 2026 Direct
John C. Jacobs NVAX Common Stock Tax liability -23.5% -69,288 225,680 03 Mar 2026 Direct
John C. Jacobs NVAX Common Stock Options Exercise 131.8% 150,167 264,130 03 Mar 2026 Direct
John C. Jacobs NVAX Restricted Stock Units Options Exercise -33.3% -150,167 300,333 03 Mar 2026 Direct
Elaine O'Hara NVAX Common Stock Tax liability -14.3% -22,429 134,642 03 Mar 2026 Direct
Elaine O'Hara NVAX Common Stock Options Exercise 55.9% 56,334 157,071 03 Mar 2026 Direct
Elaine O'Hara NVAX Restricted Stock Units Options Exercise -33.3% -56,334 112,666 03 Mar 2026 Direct
Mark J. Casey NVAX Common Stock Tax liability -11.2% -11,378 90,067 03 Mar 2026 Direct
Mark J. Casey NVAX Common Stock Options Exercise 58.6% 37,500 101,445 03 Mar 2026 Direct
Mark J. Casey NVAX Restricted Stock Units Options Exercise -50% -4,000 4,000 03 Mar 2026 Direct
James Patrick Kelly NVAX Non-statutory Stock Option NQ Award 194,000 194,000 02 Mar 2026 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .